Results 231 to 240 of about 10,911,887 (292)
Pulmonary amyloidosis presents with diverse radiological manifestations ranging from nodular lesions to diffuse interstitial abnormalities. Conventional forceps TBLB may serve different clinical roles according to disease presentation: distinguishing localized nodular amyloidosis from malignancy and providing an initial diagnostic clue to systemic ...
Masaki Tanaka +9 more
wiley +1 more source
Rare dual-clone phenomenon: concurrent λ AL amyloidosis and κ restricted B-cell lymphoproliferative disorders. [PDF]
Cetin O +4 more
europepmc +1 more source
Importance of tissue diagnosis in pulmonary amyloidosis, a rare albeit treatable cause of interstitial lung disease. ABSTRACT Pulmonary amyloidosis is a rare manifestation of amyloid deposition which can present as a rare albeit treatable cause of interstitial lung disease.
Kai Wen Hwang +3 more
wiley +1 more source
The molecular landscape of AL amyloidosis. [PDF]
Zvida-Bloch T +4 more
europepmc +1 more source
The identification of the glymphatic system (GS) and meningeal lymphatic vessels (mLVs) challenges the century‐old “immune‐privileged” dogma of the central nervous system (CNS), establishing a critical mechanistic link between impaired waste clearance (Aβ/tau) and the pathogenesis of Alzheimer's disease (AD).
Bingbing Song +10 more
wiley +1 more source
Case Report: Contrast adenosine stress echocardiography revealing microvascular dysfunction in cardiac AL amyloidosis. [PDF]
Dai Y +5 more
europepmc +1 more source
Neuronal senescence‐like states arise from convergent intrinsic and disease‐associated stressors and are linked to persistent dysfunction, SASP‐like signaling, and altered glial interactions. Because no single marker is definitive in post‐mitotic neurons, multimarker and context‐dependent frameworks are required to define their role in ...
Miraj Ud Din Momand +2 more
wiley +1 more source
Serum and Tissue Light-Chains as Disease Biomarkers in AL Amyloidosis. [PDF]
Aimo A +12 more
europepmc +1 more source
In this 28‐patient retrospective cohort, rituximab‐based regimens for IgM‐related neuropathy yielded significant, sustained functional and neurological improvements over a 2‐year follow‐up. Furthermore, reductions in serum IgM levels correlated with improved Inflammatory Neuropathy Cause and Treatment disability scores, highlighting the long‐term ...
Maria Gavriatopoulou +15 more
wiley +1 more source

